| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8736562 | Best Practice & Research Clinical Rheumatology | 2017 | 14 Pages |
Abstract
Disease severity varies from mild to life threatening, and one of the most feared complications is AA amyloidosis. Effective therapies are available for many of the syndromes, including colchicine, IL-1 blockade and anti-TNF therapies, and there is an increasing interest in blocking interferon pathways.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Helen J. Lachmann,